10-Q: Protalix BioTherapeutics Reports Third Quarter 2024 Financial Results, Highlights Elfabrio Commercial Progress

Protalix BioTherapeutics reports a mixed third quarter with increased product sales offset by a decrease in R&D revenue, while highlighting the full repayment of convertible notes and progress in clinical trials.

Summary

• Protalix BioTherapeutics reported a net loss of $3.6 million for the nine months ended September 30, 2024, but a net income of $3.2 million for the three months ended September 30, 2024.
• Total revenue for the nine months was $35.2 million, down from $55 million in the same period last year, primarily due to a significant decrease in license and R&D service revenue.
• Revenue from selling goods increased to $34.8 million for the nine months, up from $30.3 million in the prior year period, driven by sales of Elfabrio and Elelyso.
• The company's cost of goods sold increased to $20.4 million for the nine months, up from $14.1 million in the prior year period.
• Research and development expenses decreased to $8.8 million for the nine months, down from $14 million in the prior year period, reflecting the completion of the Fabry clinical program.
• Selling, general, and administrative expenses decreased to $9.2 million for the nine months, down from $10.8 million in the prior year period.
• The company fully repaid its 7.5% Senior Secured Convertible Notes due in September 2024, using available cash.
• As of September 30, 2024, Protalix had $27.4 million in cash and cash equivalents.
• The company initiated a Phase I clinical trial for PRX-115, a treatment for uncontrolled gout, and is preparing for a Phase II trial expected to commence in the second half of 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments such as increased product sales and the repayment of debt, the significant decrease in total revenue and the net loss for the nine-month period temper the overall outlook. The company's future success is also dependent on several factors, including the commercial success of its products and the outcome of its clinical trials.

Positives

• Revenue from selling goods increased by 15% for the nine months ended September 30, 2024, indicating strong product demand.
• Research and development expenses decreased by 37% for the nine months ended September 30, 2024, due to the completion of the Fabry clinical program.
• The full repayment of the convertible notes eliminates a significant financial obligation.
• The company has initiated a Phase I clinical trial for PRX-115, a treatment for uncontrolled gout, and is preparing for a Phase II trial.
• The company reported a net income of $3.2 million for the three months ended September 30, 2024, a significant improvement compared to the same period in 2023.

Negatives

• Total revenue decreased by 36% for the nine months ended September 30, 2024, due to a significant decrease in license and R&D service revenue.
• Cost of goods sold increased by 45% for the nine months ended September 30, 2024, impacting overall profitability.
• The company reported a net loss of $3.6 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents decreased from $23.6 million at the end of 2023 to $27.4 million as of September 30, 2024.

Risks

• The company's operations are subject to risks related to the ongoing conflict in Israel, which could disrupt operations and supply chains.
• The company's future success depends on the commercial success of Elfabrio and Elelyso, which are subject to market acceptance, competition, and regulatory actions.
• The company may need to raise additional capital to fund its research and development activities, which may be difficult given the volatility of its stock price.
• The company is dependent on third-party providers for services and supplies, including clinical trial services.
• The company faces risks related to the development of competing therapies and technologies by other companies.

Future Outlook

The company expects to continue to incur significant expenditures in the near future due to research and development efforts with respect to its product candidates and believes that its cash and cash equivalents as of September 30, 2024 are sufficient to satisfy its capital needs for at least 12 months from the date that these financial statements are issued. The company also anticipates increased revenues from the sales of Elfabrio and Elelyso.

Management Comments

• The company is committed to leveraging its track record of success as it progresses with the development of treatments for rare and orphan diseases.
• The company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases.
• The company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities.
• The company is also exploring novel platform technologies.

Industry Context

The report highlights Protalix's position in the rare disease market, particularly in enzyme replacement therapies for Fabry and Gaucher diseases. The company's focus on its proprietary ProCellEx platform and its expansion into new therapeutic areas like gout with PRX-115 aligns with industry trends towards innovative treatments for unmet medical needs. The competitive landscape includes established players like Sanofi and Takeda, as well as emerging companies in the rare disease space.

Comparison to Industry Standards

• Protalix's Elfabrio competes with Sanofi's Fabrazyme and Takeda's Replagal in the Fabry disease market, which is projected to reach $3.3 billion in annual sales by 2030. The company's BALANCE study showed comparable efficacy to agalsidase beta, but did not demonstrate non-inferiority due to lack of data to support a non-inferiority margin.
• In the Gaucher disease market, Protalix's Elelyso competes with Sanofi's Cerezyme and Takeda's Vpriv. The global market for Gaucher disease is forecasted to be approximately $1.65 billion in 2024.
• The company's PRX-115, a PEGylated uricase for gout, is targeting a market where Krystexxa (pegloticase) is a competitor, but has a black box warning for anaphylaxis. Protalix's PRX-115 aims to offer a safer and more effective alternative.
• The company's ProCellEx platform is a unique plant-based protein expression system, differentiating it from competitors that use mammalian cell-based systems.

Stakeholder Impact

• Shareholders may be concerned about the net loss for the nine-month period and the potential need for additional capital.
• Employees may be affected by the company's financial performance and any potential changes in operations.
• Customers and patients may benefit from the company's continued development of new therapies.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to present the preliminary results of the PRX-115 Phase I clinical trial at an upcoming scientific meeting.
• The company has commenced preparations for a Phase II clinical trial of PRX-115, which is expected to commence in the second half of 2025.
• The company will continue to monitor the ongoing conflict in Israel and its potential impact on operations.

Key Dates

Keywords

Protalix BioTherapeutics, Elfabrio, Elelyso, Fabry disease, Gaucher disease, PRX-115, gout, clinical trials, biopharmaceutical, enzyme replacement therapy, recombinant proteins, financial results